Search research articles
Contact Us
Filters
Showing results (21-30 of 30) with videos related to
Page
of 3
Sort By:
You have reached the last page of results.
This site can display upto 30 results.
Journal of Medical Economics
|
November 14, 2018
A review and validation of overall survival extrapolation in health technology assessments of cancer immunotherapy by the National Institute for Health and Care Excellence: how did the initial best estimate compare to trial data subsequently made available?
Ash Bullement, Yang Meng, Miranda Cooper, et al.
International Journal of Technology Assessment in Health Care
|
July 11, 2020
Real-world evidence use in assessments of cancer drugs by NICE
Ash Bullement, Tanja Podkonjak, Mark J Robinson, et al.
Pharmacoeconomics
|
August 29, 2024
MPES-R: Multi-Parameter Evidence Synthesis in R for Survival Extrapolation-A Tutorial
Ash Bullement, Mark Edmondson-Jones, Patricia Guyot, et al.
Pharmacoeconomics - Open
|
January 26, 2019
Cost Effectiveness of Avelumab for Metastatic Merkel Cell Carcinoma
Ash Bullement, Paul Nathan, Anna Willis, et al.
Pharmacoeconomics
|
April 27, 2024
Advances in Addressing Patient Heterogeneity in Economic Evaluation: A Review of the Methods Literature
Gemma E Shields, Paul Clarkson, Ash Bullement, et al.
Plos One
|
September 15, 2015
Double Relapsed and/or Refractory Multiple Myeloma: Clinical Outcomes and Real World Healthcare Costs
Sarah Gooding, I-Jun Lau, Mimi Sheikh, et al.
Pharmacoeconomics
|
September 3, 2020
Voretigene Neparvovec for Treating Inherited Retinal Dystrophies Caused by RPE65 Gene Mutations: An Evidence Review Group Perspective of a NICE Highly Specialised Technology Appraisal
Caroline Farmer, Ash Bullement, David Packman, et al.
Future Oncology (London, England)
|
May 19, 2025
Cost-effectiveness of cetuximab-containing regimens for squamous cell carcinoma of the head and neck in Italy
Philipp Ivanyi, Ash Bullement, Andrea Botticelli, et al.
Blood Advances
|
April 25, 2024
"Don't keep me waiting": estimating the impact of reduced vein-to-vein time on lifetime US 3L+ LBCL patient outcomes
Sachin Vadgama, Marcelo C Pasquini, Richard T Maziarz, et al.
Future Oncology (London, England)
|
August 2, 2023
Cost-effectiveness analysis for avelumab first-line maintenance treatment of advanced urothelial carcinoma in Scotland
Simone Critchlow, Ash Bullement, Simon Crabb, et al.
Page
of 3
Search research articles
Search
Showing results (21-30 of 30) with videos related to
Sort By:
Page
of 3
You have reached the last page of results.
This site can display upto 30 results.
Journal of Medical Economics
|
November 14, 2018
A review and validation of overall survival extrapolation in health technology assessments of cancer immunotherapy by the National Institute for Health and Care Excellence: how did the initial best estimate compare to trial data subsequently made available?
Ash Bullement, Yang Meng, Miranda Cooper, et al.
International Journal of Technology Assessment in Health Care
|
July 11, 2020
Real-world evidence use in assessments of cancer drugs by NICE
Ash Bullement, Tanja Podkonjak, Mark J Robinson, et al.
Pharmacoeconomics
|
August 29, 2024
MPES-R: Multi-Parameter Evidence Synthesis in R for Survival Extrapolation-A Tutorial
Ash Bullement, Mark Edmondson-Jones, Patricia Guyot, et al.
Pharmacoeconomics - Open
|
January 26, 2019
Cost Effectiveness of Avelumab for Metastatic Merkel Cell Carcinoma
Ash Bullement, Paul Nathan, Anna Willis, et al.
Pharmacoeconomics
|
April 27, 2024
Advances in Addressing Patient Heterogeneity in Economic Evaluation: A Review of the Methods Literature
Gemma E Shields, Paul Clarkson, Ash Bullement, et al.
Plos One
|
September 15, 2015
Double Relapsed and/or Refractory Multiple Myeloma: Clinical Outcomes and Real World Healthcare Costs
Sarah Gooding, I-Jun Lau, Mimi Sheikh, et al.
Pharmacoeconomics
|
September 3, 2020
Voretigene Neparvovec for Treating Inherited Retinal Dystrophies Caused by RPE65 Gene Mutations: An Evidence Review Group Perspective of a NICE Highly Specialised Technology Appraisal
Caroline Farmer, Ash Bullement, David Packman, et al.
Future Oncology (London, England)
|
May 19, 2025
Cost-effectiveness of cetuximab-containing regimens for squamous cell carcinoma of the head and neck in Italy
Philipp Ivanyi, Ash Bullement, Andrea Botticelli, et al.
Blood Advances
|
April 25, 2024
"Don't keep me waiting": estimating the impact of reduced vein-to-vein time on lifetime US 3L+ LBCL patient outcomes
Sachin Vadgama, Marcelo C Pasquini, Richard T Maziarz, et al.
Future Oncology (London, England)
|
August 2, 2023
Cost-effectiveness analysis for avelumab first-line maintenance treatment of advanced urothelial carcinoma in Scotland
Simone Critchlow, Ash Bullement, Simon Crabb, et al.
Page
of 3